within Pharmacolibrary.Drugs.ATC.N;

model N05BA18
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.00035,
    adminDuration  = 600,
    adminMass      = 0.001,
    adminCount     = 1,
    Vd             = 0.0014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Ethyl loflazepate is a benzodiazepine derivative with anxiolytic, anticonvulsant, and sedative properties. It is used for treating anxiety and related disorders, predominantly in some European and Asian countries, but it is not widely approved in the United States. Its use has declined due to concerns over benzodiazepine dependence and safer alternatives.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates are based on healthy adult volunteers receiving single oral doses.</p><h4>References</h4><ol><li><p>Ba, BB, et al., &amp; Cano, JP (1989). Effect of renal failure on the pharmacokinetics of ethyl loflazepate (Victan) in man. <i>Fundamental &amp; clinical pharmacology</i> 3(1) 11–17. DOI:<a href=&quot;https://doi.org/10.1111/j.1472-8206.1989.tb00025.x&quot;>10.1111/j.1472-8206.1989.tb00025.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2714728/&quot;>https://pubmed.ncbi.nlm.nih.gov/2714728</a></p></li><li><p>Ba, BB, et al., &amp; Cano, JP (1989). Pharmacokinetic modeling of ethyl loflazepate (Victan) and its main active metabolites. <i>Annals of biomedical engineering</i> 17(6) 633–646. DOI:<a href=&quot;https://doi.org/10.1007/BF02367467&quot;>10.1007/BF02367467</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2574017/&quot;>https://pubmed.ncbi.nlm.nih.gov/2574017</a></p></li><li><p>Cautreels, W, &amp; Jeanniot, JP (1980). Quantitative analysis of CM 6912 (ethyl loflazepate) and its metabolites in plasma and urine by chemical ionization gas chromatography mass spectrometry. Application to pharmacokinetic studies in man. <i>Biomedical mass spectrometry</i> 7(11-12) 565–571. DOI:<a href=&quot;https://doi.org/10.1002/bms.1200071124&quot;>10.1002/bms.1200071124</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6112027/&quot;>https://pubmed.ncbi.nlm.nih.gov/6112027</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05BA18;
